Patents by Inventor James F. Oliviero, III

James F. Oliviero, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20240041816
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: December 28, 2022
    Publication date: February 8, 2024
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20190269645
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: October 8, 2018
    Publication date: September 5, 2019
    Applicant: Keryx Biopharmaceuticals, Inc.
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
  • USE OF FERRIC CITRATE IN THE TREATMENT OF AND THE REDUCTION OF MORTALITY AND MORBIDITY RELATED TO ADVERSE CARDIAC EVENTS IN CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20160256486
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 8, 2016
    Applicant: Keryx Biopharmaceuticals, Inc.
    Inventors: Enrique Poradosu, Ron Bentsur, James F. Oliviero, III
  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20150079168
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: October 24, 2014
    Publication date: March 19, 2015
    Applicant: KERYX BIOPHARMACEUTICALS, INC.
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20140234416
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: Keryx Biopharmaceuticals, Inc.
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
  • USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS
    Publication number: 20130345303
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 26, 2013
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur